CRL Charles River Laboratories International, Inc. stock chart & analysis
Conviction 11HealthcareScan · Fri, Nov 6, 2026Charles River Laboratories International, Inc. (CRL) closed at $337.52 (+7.83%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 54, RS Rating 97, -11.1% from its 52-week high, +69.1% year to date. Sector: Healthcare · Services-Commercial Physical & Biological Research.
Financials as of Sat, Sep 26, 2026 · quarterly.
CRL technical analysis
Trend
CRL is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 10.4% above the 50-day ($305.59) and 50.2% above the 200-day ($224.56). ADX(14) at 36 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 54, in the bullish half of its range. MACD crossed below its signal line 2 sessions ago. Its RS Rating of 97 puts its weighted 12-month performance ahead of about 97% of the US market.
Volume and volatility
Volume on the latest session ran 0.5× its 20-day average. It trades about $423.5M a day on average. ATR(14) is $17.49, 5.2% of price — its typical daily range.
Key levels
The chart pattern's support is $286.52 and its resistance $356.46. The 52-week range is $146.20 to $379.63; price is 11.1% below the high and 130.8% above the low. The VWAP anchored at the 52-week high is $344.35, above price.
Performance
CRL returned -6.1% (1 week), +13.2% (1 month), +21.8% (3 months), +89.9% (6 months), +101.2% (1 year), +69.1% (year to date).
About Charles River Laboratories International, Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Services-Commercial Physical & Biological Research · Listed 2000 · 19,700 employees
Recent news
- Charles River Laboratories International (CRL) Lifted Guidance, Is The Stock Already Pricey?Yahoo Finance · Thu, Nov 5, 2026
- Will Earnings Beat Change Charles River Laboratories' (CRL) NarrativeYahoo Finance · Thu, Nov 5, 2026
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: Ownership stake amendedSEC EDGAR · Thu, Nov 5, 2026
- Charles River Laboratories International Q3 Earnings Call HighlightsMarketbeat · Thu, Nov 5, 2026
- Charles River Laboratories International Inc (CRL) (Q3 2026) Earnings Call Highlights: ...Yahoo Finance · Thu, Nov 5, 2026
- Charles River Laboratories International, Inc. Q3 2026 Earnings Call SummaryMoby · Wed, Nov 4, 2026
- Charles River Laboratories Stock Pulls A Bear Move As Rats And Mice RetreatYahoo Finance · Wed, Nov 4, 2026
- Charles River (CRL) Q3 2026 Earnings Call TranscriptMotley Fool · Wed, Nov 4, 2026
- Bioburden Testing - Global Strategic Business Report 2026: Capture the $3.6B Market by 2032 as Becton Dickinson, Charles River, SGS, and Pacific Biolabs Drive 14.7% CAGRYahoo Finance · Wed, Nov 4, 2026
- Charles River Q3 Earnings & Revenues Top Estimates, Stock RisesYahoo Finance · Wed, Nov 4, 2026
Congress activity
Disclosed STOCK Act trades in CRL · 5 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Jefferson Shreve house · R · IN · traded 2025-05-12 | Sell | $15K–$50K | 2025-05-12 | 2025-06-22 | |
Jefferson Shreve house · R · IN · traded 2025-05-08 | Buy | $15K–$50K | 2025-05-08 | 2025-06-22 | |
 Rob Bresnahan house · PA · traded 2025-05-15 | Sell | $1K–$15K | 2025-05-15 | 2025-05-31 | |
Rob Bresnahan house · PA · traded 2025-04-08 | Buy | $15K–$50K | 2025-04-08 | 2025-05-08 | |
 Julie Johnson house · D · TX · traded 2025-01-15 | Buy | $1K–$15K | 2025-01-15 | 2025-02-12 |
Insider activity
SEC Form 4 transactions in CRL · open-market 3 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
FOSTER JAMES C Director · Common Stock · 2026-10-22 | Sell | 24.04K | $8.4M | 2026-10-22 | 2026-10-26 |
FOSTER JAMES C Director · Stock Options (Right to Buy) · 2026-10-22 | Exercise | 24.04K | — | 2026-10-22 | 2026-10-26 |
FOSTER JAMES C Director · Common Stock · 2026-10-22 | Exercise | 24.04K | $5.9M | 2026-10-22 | 2026-10-26 |
Parisotto Shannon M CEVP, Disc & Safety Assessment · Common Stock · 2026-10-05 | Exercise | 981 | $204K | 2026-10-05 | 2026-10-07 |
Parisotto Shannon M CEVP, Disc & Safety Assessment · Common Stock · 2026-10-05 | Sell | 981 | $303K | 2026-10-05 | 2026-10-07 |
Parisotto Shannon M CEVP, Disc & Safety Assessment · Stock Options (Right to Buy) · 2026-10-05 | Exercise | 981 | — | 2026-10-05 | 2026-10-07 |
FOSTER JAMES C Director · Stock Options (Right to Buy) · 2026-08-25 | Exercise | 21.13K | — | 2026-08-25 | 2026-08-27 |
FOSTER JAMES C Director · Common Stock · 2026-08-25 | Exercise | 21.13K | $4.1M | 2026-08-25 | 2026-08-27 |
FOSTER JAMES C Director · Common Stock · 2026-08-25 | Exercise | 12.43K | $2.6M | 2026-08-25 | 2026-08-27 |
FOSTER JAMES C Director · Common Stock · 2026-08-25 | Sell | 33.56K | $10M | 2026-08-25 | 2026-08-27 |
SEC filings
EDGAR filings in CRL · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.